Crispr Therapeutics shares tumble after significant earnings miss
Kevin S. Bloomfield, a director at Carter Bankshares, Inc. (NASDAQ:CARE), has sold 1,629 shares of the company’s common stock. The transaction, which took place on June 12, 2025, was executed at an average price of $16.806 per share, resulting in a total sale value of $27,376. The sale occurred with the stock trading near InvestingPro’s Fair Value estimate, in a company currently valued at $382 million. Following this transaction, Bloomfield holds 16,418 shares in the company. With analyst price targets ranging from $21 to $22 and the stock showing a strong 35% return over the past year, InvestingPro analysis reveals additional insights through its comprehensive research reports, available for over 1,400 US stocks.
In other recent news, Carter Bankshares, Inc. announced the results of its 2025 Annual Meeting of Shareholders, where 11 directors were elected to serve until the next meeting. The meeting also included a non-binding advisory vote on executive compensation, which received significant shareholder approval. Additionally, the appointment of Crowe LLP as independent auditors for the fiscal year ending December 31, 2025, was ratified. In another development, Carter Bankshares unveiled a $20 million share repurchase program approved by its Board of Directors. This initiative will be active until May 14, 2026, and allows for flexibility in the timing and method of share purchases. Meanwhile, board member E. Warren Matthews announced his retirement, effective at the upcoming Annual Meeting, leading to a planned reduction of the board from 12 to 11 members. These developments reflect Carter Bankshares’ ongoing governance and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.